RNAIII-inhibiting peptide improves efficacy of clinically used antibiotics in a murine model of staphylococcal sepsis

This publication has 29 references indexed in Scilit:

• Prophylactic Efficacy of Topical Temporin A and RNAIII-Inhibiting Peptide in a Subcutaneous Rat Pouch Model of Graft Infection Attributable to Staphylococci With Intermediate Resistance to Glycopeptides
  Circulation, 2003
• RNA III Inhibiting Peptide Inhibits In Vivo Biofilm Formation by Drug-Resistant Staphylococcus aureus
  Antimicrobial Agents and Chemotherapy, 2003
• Use of the Quorum‐Sensing Inhibitor RNAIII‐Inhibiting Peptide to Prevent Biofilm Formation In Vivo by Drug‐ResistantStaphylococcus epidermidis
  The Journal of Infectious Diseases, 2003
• Prevention of Staphylococcus aureus biofilm on dialysis catheters and adherence to human cells
  Kidney International, 2003
• RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis
  Peptides, 2001
• Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
  Critical Care Medicine, 2001
• Regulation of Staphylococcus aureus Pathogenesis via Target of RNAIII-activating Protein (TRAP)
  Journal of Biological Chemistry, 2001
• Autoinducer of Virulence As a Target for Vaccine and Therapy AgainstStaphylococcus aureus
  Science, 1998
• The cell wall components peptidoglycan and lipoteichoic acid from Staphylococcus aureus act in synergy to cause shock and multiple organ failure.
  Proceedings of the National Academy of Sciences, 1995
• The Pathogenesis of Sepsis
  Annals of Internal Medicine, 1991